Terms: = Lung cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Prognosis
141 results:
1. The diagnosis and treatment for primary cardiac angiosarcoma with n-ras gene mutation and MSI-L: A case report and review of the literature.
Sun J; Wei T; Sun B; Su J; Liu H; Wang D; Li X
Medicine (Baltimore); 2023 Dec; 102(51):e36682. PubMed ID: 38134104
[TBL] [Abstract] [Full Text] [Related]
2. The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.
Honda T; Seto K; Endo S; Takemoto A; Tanimoto K; Kobayashi M; Kitano M; Sakakibara R; Mitsumura T; Ishibashi H; Inazawa J; Tanaka T; Miyazaki Y; Okubo K
Cancer Med; 2023 Oct; 12(19):19406-19413. PubMed ID: 37712717
[TBL] [Abstract] [Full Text] [Related]
3. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
4. Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
Aoki K; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Nishizawa T; Fukuda H; Ohashi K; Arai K; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Maruyama T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Mizuno H; Tsunoda H; Ochiai A
Cancer Res Commun; 2023 Jun; 3(6):1026-1040. PubMed ID: 37377611
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological Features and prognosis of lung Adenocarcinoma Patients With k-ras Gene Mutation.
Sun D; Liu Y; Li P; Yang P; Yu G
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):406-413. PubMed ID: 37338109
[TBL] [Abstract] [Full Text] [Related]
6. Establishment of a novel experimental system using single cell-derived pleomorphic rhabdomyosarcoma cell lines expressing k-rasG12V and deficient in p53.
Saito H; Suzuki N
Exp Anim; 2023 Nov; 72(4):446-453. PubMed ID: 37081671
[TBL] [Abstract] [Full Text] [Related]
7. The Tumorigenic Effect of the High Expression of Ladinin-1 in lung Adenocarcinoma and Its Potential as a Therapeutic Target.
Hu L; Liu Y; Fu C; Zhao J; Cui Q; Sun Q; Wang H; Lu L; Dai H; Xu X; Yang W
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770773
[TBL] [Abstract] [Full Text] [Related]
8. FAM83A antisense RNA 1 (
Zhao H; Wang Y; Wu X; Zeng X; Lin B; Hu S; Zhang S; Li Y; Zhou Z; Zhou Y; Du C; Beer DG; Bai S; Chen G
Bioengineered; 2022 May; 13(5):13312-13327. PubMed ID: 35635086
[TBL] [Abstract] [Full Text] [Related]
9. hras Q61L Mutation as a Possible Target for Non-Small Cell lung cancer: Case Series and Review of Literature.
Mathiot L; Herbreteau G; Robin S; Fenat C; Bennouna J; Blanquart C; Denis M; Pons-Tostivint E
Curr Oncol; 2022 May; 29(5):3748-3758. PubMed ID: 35621690
[TBL] [Abstract] [Full Text] [Related]
10. Targeting IL-1β as an immunopreventive and therapeutic modality for k-ras-mutant lung cancer.
Yuan B; Clowers MJ; Velasco WV; Peng S; Peng Q; Shi Y; Ramos-Castaneda M; Zarghooni M; Yang S; Babcock RL; Chang SH; Heymach JV; Zhang J; Ostrin EJ; Watowich SS; Kadara H; Moghaddam SJ
JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35471938
[TBL] [Abstract] [Full Text] [Related]
11. Novel mutation signatures in the prognosis of EGFR-TKIs targeted therapy for non-small cell lung cancer patients based on the 1000-gene panel sequencing.
Zhang H; Jiang D; Jin H; Cui YZ; Wei SJ; Li Y; Dong Q; Zuo J; Tian CJ; Yan F; Wang XW
Neoplasma; 2022 Mar; 69(2):352-360. PubMed ID: 35081725
[TBL] [Abstract] [Full Text] [Related]
12. [Clinical analysis of 12 cases of acute myeloid leukemia complicated with synchronous primary solid tumor].
Mi RH; Dang HB; Chen L; Han YL; Wang MF; Zhang YL; Chen L; Li DB; Wei XD
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3323-3327. PubMed ID: 33202495
[No Abstract] [Full Text] [Related]
13. Identification of a novel subpopulation of Caspase-4 positive non-small cell lung cancer patients.
Terlizzi M; Colarusso C; De Rosa I; Somma P; Curcio C; Aquino RP; Panico L; Salvi R; Zito Marino F; Botti G; Pinto A; Sorrentino R
J Exp Clin Cancer Res; 2020 Nov; 39(1):242. PubMed ID: 33187551
[TBL] [Abstract] [Full Text] [Related]
14. Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer.
Deng S; Ramos-Castaneda M; Velasco WV; Clowers MJ; Gutierrez BA; Noble O; Dong Y; Zarghooni M; Alvarado L; Caetano MS; Yang S; Ostrin EJ; Behrens C; Wistuba II; Stabile LP; Kadara H; Watowich SS; Moghaddam SJ
Carcinogenesis; 2020 Nov; 41(11):1529-1542. PubMed ID: 32603404
[TBL] [Abstract] [Full Text] [Related]
15. [A Rare Case of Pulmonary Epithelial-myoepithelial Carcinoma: Case Report and Literature Review].
Chen L; Li Q; Fu G; Ge M
Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):127-132. PubMed ID: 32093457
[TBL] [Abstract] [Full Text] [Related]
16. Treatment of consistent BRAF/hras gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report.
Guan J; Luo Z; Xiao Z; Xie Y; Lin L
BMC Cancer; 2019 Dec; 19(1):1188. PubMed ID: 31805975
[TBL] [Abstract] [Full Text] [Related]
17. Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia.
Ishikawa G; Fujiwara N; Hirschfield H; Varricchio L; Hoshida Y; Barosi G; Rosti V; Padilla M; Mazzarini M; Friedman SL; Hoffman R; Migliaccio AR
Exp Hematol; 2019 Nov; 79():16-25.e3. PubMed ID: 31678370
[TBL] [Abstract] [Full Text] [Related]
18. Multiple MicroRNAs synergistically promote tolerance to epidermal growth factor receptor-targeted drugs in smoked lung cancer therapies.
Pan L; Wang H; Jiang C; Li W; Chen Y; Ying G
J Cancer Res Ther; 2019; 15(4):876-881. PubMed ID: 31436246
[TBL] [Abstract] [Full Text] [Related]
19. KRAS Exon 3 and PTEN Exon 7 Mutations in Small-cell lung cancer.
Lei L; Jiang ZM; Li CH; Lu HY
Curr Med Sci; 2019 Jun; 39(3):379-384. PubMed ID: 31209806
[TBL] [Abstract] [Full Text] [Related]
20. [The clinical and pathological features, biomarker characteristics and prognosis analysis of lung adenosquamous carcinoma].
Zhou SY; Xue Q; Ying JM; Hu XS; Yang JL; Lin H; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):50-55. PubMed ID: 30678417
[No Abstract] [Full Text] [Related]
[Next]
